Subtype
Liver Carcinoma
CI-CAN-00001073Explore in graph →
783 active trials14 approved drugs17 evidence items
- NCIt
- C7927
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001073Explore in graph →
Clinical trials
3,367 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (386)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05903456 | Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma | unknown | Phase 2 | 20 | Zhejiang Cancer HospitalOTHER | 0 | Jun 15, 2023 | clinicaltrials |
| NCT05886465 | HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT04631731 |
| Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity(ICEMELT) |
| unknown |
| Phase 1 / Phase 2 |
| 200 |
| Western Sydney Local Health DistrictOTHER |
| 1 |
| Jun 1, 2023 |
| clinicaltrials |
| NCT05883176 | TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria(B-TACE) | unknown | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05872841 | H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis | unknown | Phase 2 | 38 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 24, 2023 | clinicaltrials |
| NCT05134532 | Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC(HCC) | unknown | Phase 2 | 40 | CHA UniversityOTHER | 1 | Apr 26, 2023 | clinicaltrials |
| NCT04454905 | Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT04652440 | Ablation Combined With PD-1 in HCC: Phase II Study | unknown | Phase 1 / Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05400902 | HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 17 | Binkui LiOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05809869 | Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma | unknown | Phase 2 | 25 | The University of Hong KongOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT04368078 | Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 76 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04443309 | Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC | unknown | Phase 1 / Phase 2 | 53 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05048017 | Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04663035 | Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC | unknown | Phase 2 | 120 | Ming ZhaoOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT05407519 | A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection | unknown | Phase 2 | 40 | Anhui Provincial HospitalOTHER_GOV | 1 | Mar 22, 2023 | clinicaltrials |
| NCT05616390 | Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05408221 | the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma(HCC) | unknown | Phase 2 / Phase 3 | 576 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05760430 | The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma | unknown | Phase 2 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05760599 | Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T | unknown | Phase 2 | 30 | Shi MingOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT04992143 | TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC | unknown | Phase 2 | 20 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05029973 | HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT04911959 | Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC | unknown | Phase 1 / Phase 2 | 50 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05312216 | Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 25 | Zhejiang UniversityOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT04213118 | Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence(ALTER-H-004) | unknown | Phase 2 | 30 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05672537 | Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk | unknown | Phase 2 | 70 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT05280444 | Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma | unknown | Phase 2 / Phase 3 | 216 | Zhongda HospitalOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05344924 | TACE Combined With Penpulimab and Anlotinib for Advanced HCC | unknown | Phase 2 / Phase 3 | 109 | Zhongda HospitalOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05578430 | AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING) | unknown | Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 0 | Dec 15, 2022 | clinicaltrials |
| NCT04503902 | Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma(HCC) | unknown | Phase 1 / Phase 2 | 46 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Nov 29, 2022 | clinicaltrials |
| NCT05620004 | Safety and Efficacy of Bifidobacterium Therapy in Patients With Advanced Liver Cancer Receiving Immunotherapy | unknown | Phase 1 / Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05617430 | Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 43 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT04718909 | Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC(REGSIN) | unknown | Phase 2 | 166 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT05582278 | HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC | unknown | Phase 2 | 60 | Wen LiOTHER | 1 | Oct 17, 2022 | clinicaltrials |
| NCT03864211 | Thermal Ablation Followed by Immunotherapy for HCC | unknown | Phase 1 / Phase 2 | 145 | Xiangya Hospital of Central South UniversityOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05550025 | TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer | unknown | Phase 2 | 26 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT05545124 | Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence | unknown | Phase 2 | 32 | Henan Cancer HospitalOTHER_GOV | 0 | Sep 19, 2022 | clinicaltrials |
| NCT05544253 | Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC | unknown | Phase 2 / Phase 3 | 68 | West China HospitalOTHER | 1 | Sep 16, 2022 | clinicaltrials |
| NCT05535647 | Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT05519410 | Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 29, 2022 | clinicaltrials |
| NCT04782804 | Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence | unknown | Phase 1 / Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05493332 | HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC | unknown | Phase 2 | 93 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Aug 18, 2022 | clinicaltrials |
| NCT05290116 | HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 17 | Yunfei YuanOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT04174781 | Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC | unknown | Phase 2 | 61 | Zhejiang UniversityOTHER | 1 | Jun 9, 2022 | clinicaltrials |
| NCT05396937 | Efficacy and Safety of T+A+RAD in HCC | unknown | Phase 2 | 42 | Fudan UniversityOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT05214339 | A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET) | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT05111366 | TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection(ALTER-H006) | unknown | Phase 2 | 37 | Xianhai MaoOTHER | 1 | May 4, 2022 | clinicaltrials |
| NCT05290220 | HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 60 | Shanghai Henlius BiotechINDUSTRY | 0 | May 3, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jun 15, 2023source: clinicaltrials